Treatment of young adults with Philadelphia‐negative acute lymphoblastic leukemia and lymphoblastic lymphoma: Hyper‐CVAD vs. pediatric‐inspired regimens. Issue 10 (3rd September 2018)

• Record Type: Journal Article
• Authors: Siegel, Stuart E.; Advani, Anjali; Seibel, Nita; Muffly, Lori; Stock, Wendy; Luger, Selina; Shah, Bijal; DeAngelo, Daniel J.; Freyer, David R.; Douer, Dan; Johnson, Rebecca H.; Hayes‐Lattin, Brandon; Lewis, Mark; Jaboin, Jerry J.; Coccia, Peter F.; Bleyer, Archie
• Is Part Of: American journal of hematology. Volume 93:Issue 10(2018:Oct.)
• Page Start: 1254
• Page End: 1266
• Publication Date: 2018-09-03
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.25229
• Languages: English
• ISSNs: 0361-8609

Abstract

Abstract: For young adults with acute lymphoblastic leukemia, pediatric‐based regimens are likely to provide the following when compared to hyper‐CVAD regimens: better disease control, less hospitalization time, diminished acute toxicities, decreased financial cost, more quality‐adjusted life years, and fewer adverse late effects, such as infertility, myelodysplasia, and second malignant neoplasms. There are also reasons to expect less cardiac and cognitive dysfunction after pediatric regimens. The improved quality and quantity of life associated with pediatric regimens renders them preferable to hyper‐CVAD regimens for the treatment of Philadelphia‐negative B‐precursor or T‐cell acute lymphoblastic leukemia and lymphoblastic lymphoma in young adults.